Brett Matthew Hall

CSO Brett Matthew Hall purchases 6,035 shares of IMRX at $4.15 amid -59.3% decline from 52-week high

Brett Matthew Hall, Chief Scientific Officer, acquired 6,035 shares at $4.15 on 2026-06-15, increasing his holdings by 1.6% to 382,531 shares. This purchase occurs as the stock is down 59.3% from its 52-week high of $10.08 and has declined 20.5% over the past 30 days. His cross-ticker track record shows 4 prior open-market buys with a 90-day win rate of 75.00% and average 90-day return of +123.1%, suggesting a history of favorable entry timing. However, at IMRX specifically, his track record is mixed: three prior buys (2025-06-20, 2025-06-23, and 2026-01-15) generated strong 90-day returns ranging from +25.8% to +281.1%, but one buy (2024-03-20) resulted in a -48.2% 90-day decline. The company faces significant headwinds: current-quarter revenue is $0.00, full-year net income is negative at $-13.5M, and annual revenue growth is -100.0%, indicating a pre-revenue or revenue-loss state with no positive earnings trajectory visible.

Chief Scientific Officer buys 2,298 shares of IMRX at $4.57; part of 4-insider cluster buy; stock down 50.5% from 52-week high

Hall Brett Matthew (Chief Scientific Officer) purchased 2,298 shares at $4.57, increasing holdings to 376,496 shares in a company generating $0.00 in latest quarterly revenue with $-14,964,875.00 net income. The stock is trading at $4.58, down 50.5% from its 52-week high and down 16.7% over the past 30 days. This purchase is part of a broader cluster pattern with 4 other insiders buying within the past 14 days, suggesting coordinated management confidence. In his prior two IMRX purchases (June 2025), Matthew's timing proved strong with 90-day returns of +68.7% and +281.1%, though a 2024 purchase returned -48.2% over 90 days; his cross-ticker track record shows 66.67% 90-day win rate with average 90d return of +155.5%, demonstrating a historical pattern of value recognition, though at a fundamentally challenged company.

Chief Scientific Officer Brett Hall bought 13,422 shares in IMRX across 2 transactions totaling $34.6K; prior buy at this ticker produced 90d loss.

Hall Matthew completed two separate purchases on 2025-06-20 and 2025-06-23, acquiring 13,422 shares at blended average price of $2.58, increasing his holdings by 3.9% to 359.3K shares. However, his prior open-market buy at IMRX on 2024-03-20 resulted in a 90-day return of -48.2%, indicating poor timing on his last discretionary accumulation at this ticker. The company remains unprofitable with net income of $-15.0M and zero quarterly revenue, while the stock has recently surged 90.9% over 30 days and 79.3% over 90 days from depressed levels. A cluster of 4 other insiders also bought within the past 14 days, suggesting potential coordination or response to a common signal, though this does not offset the data showing Hall's track record of unfavorable timing outcomes at this specific ticker.